Houston Methodist

Running trials

• Not yet recruiting

  Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma

  NCT07729397· Phase 1· The Methodist Hospital Research Institute· Source

• Not yet recruiting

  A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease

  NCT07929480· Phase 1/2· Kanglin Biotechnology (Hangzhou) Co., Ltd.· Source

• Recruiting

  An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

  NCT07426419· Phase 1/2· Affinia Therapeutics· Source

• Not yet recruiting

  Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

  NCT07796490· Phase 1/2· The Methodist Hospital Research Institute· Source

• Not yet recruiting

  A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

  NCT06458907· P+F Products + Features USA Inc.· Source

• Enrolling by invitation

  Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

  NCT07197788· Endogenex, Inc.· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  A Study of LY3971297 in Participants With Heart Failure

  NCT07547540· Phase 1· Eli Lilly and Company· Source

• Recruiting

  TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

  NCT06251544· Phase 1· Baylor College of Medicine· Source

• Recruiting

  PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

  NCT07232069· Phase 3· Duke University· Source

• Recruiting

  Stem Cells for Erectile Dysfunction Post RALP

  NCT07048314· Phase 1/2· The Methodist Hospital Research Institute· Source

• Recruiting

  Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

  NCT07673107· Phase 2· AbbVie· Source

• Recruiting

  A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

  NCT07606274· Phase 1/2· Nuevocor Pte. Ltd.· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

  NCT07220993· Phase 1· Baylor College of Medicine· Source

• Recruiting

  EVERO Drug-coated Balloon (DCB) Randomized Trial

  NCT07144150· Cook Research Incorporated· Source

• Recruiting

  Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

  NCT06345027· Phase 1· Baylor College of Medicine· Source

• Recruiting

  A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

  NCT07325526· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  NCT07280013· Phase 1· C4 Therapeutics, Inc.· Source

• Recruiting

  Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

  NCT07335601· Phase 2· Madrigal Pharmaceuticals, Inc.· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  NCT06890338· Phase 2· AbbVie· Source

• Recruiting

  Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

  NCT06906627· Duke University· Source

• Recruiting

  Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

  NCT06906640· Duke University· Source

• Recruiting

  Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

  NCT06176690· Phase 1· Baylor College of Medicine· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  NCT07175038· Phase 2· AllRock Bio, Inc.· Source

• Active, not recruiting

  SPHERE Per-AF Post-Approval Study

  NCT06858306· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Recruiting

  Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

  NCT07182279· Phase 1/2· The Methodist Hospital Research Institute· Source

• Recruiting

  Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

  NCT06898515· Reprieve Cardiovascular, Inc· Source

• Recruiting

  PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

  NCT06422871· Merit Medical Systems, Inc.· Source

• Recruiting

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Tempus AI· Source

• Recruiting

  Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

  NCT06891755· Apreo Health, Inc.· Source

• Recruiting

  The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

  NCT06854458· Brigham and Women's Hospital· Source

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

  NCT06198296· Phase 1· Baylor College of Medicine· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

  NCT06626919· Phase 1· Kite, A Gilead Company· Source

• Active, not recruiting

  Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

  NCT06704269· Phase 1/2· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

  NCT06868290· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

Showing 50 of 262.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Heart failure9 recruiting
• Bladder cancer7 recruiting
• High blood pressure7 recruiting
• Ovarian cancer7 recruiting
• Coronary artery disease6 recruiting
• Prostate cancer6 recruiting
• Pulmonary arterial hypertension6 recruiting
• Chronic kidney disease5 recruiting
• Hodgkin lymphoma5 recruiting
• Lung cancer5 recruiting
• Stroke5 recruiting
• Amyloidosis4 recruiting
• Crohn's disease4 recruiting
• Dilated cardiomyopathy4 recruiting
• Pancreatic cancer4 recruiting
• Type 2 diabetes4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Aortic stenosis3 recruiting
• Endometrial cancer3 recruiting
• Hypertrophic cardiomyopathy3 recruiting
• Kidney cancer3 recruiting
• Multiple myeloma3 recruiting
• Myasthenia gravis3 recruiting
• Atrial fibrillation2 recruiting
• Charcot-Marie-Tooth disease2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Colorectal cancer2 recruiting
• COPD2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Glioblastoma2 recruiting
• Liver cirrhosis2 recruiting
• Metastatic breast cancer2 recruiting
• Peripheral artery disease2 recruiting
• Spinal cord injury2 recruiting
• Triple-negative breast cancer2 recruiting
• Ventricular tachycardia2 recruiting
• Acute myeloid leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Cervical cancer1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Essential tremor1 recruiting
• Frontotemporal dementia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Multiple sclerosis1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Sarcoma1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Withdrawn

  CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

  NCT07297160· Phase 1· Baylor College of Medicine· Source

• Recruiting

  A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

  NCT06788535· Phase 3· Sharmila Dorbala· Source

• Completed

  Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

  NCT07095712· Phase 1/2· n-Lorem Foundation· Source

• Completed

  A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

  NCT06331299· Phase 3· UroGen Pharma Ltd.· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Duke University· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Intercept Pharmaceuticals· Source

• Withdrawn

  Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

  NCT04952584· Phase 1· Baylor College of Medicine· Source

• Completed

  Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial

  NCT06089135· Baim Institute for Clinical Research· Source

• Completed

  Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

  NCT05776225· United Therapeutics· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· Phase 1/2· Cytovation AS· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· NS Pharma, Inc.· Source

• Terminated

  An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

  NCT05369832· Phase 4· Bristol-Myers Squibb· Source

• Completed

  Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

  NCT05451212· Phase 1· Cabaletta Bio· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Recruiting

  Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

  NCT05338697· Yale University· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Incyte Corporation· Source

• Completed

  Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation

  NCT04950894· LivaNova· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Completed

  ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

  NCT05070260· Phase 2/3· Acticor Biotech· Source

• Completed

  MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Hutchmed· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine

  NCT03762291· Phase 1· Baylor College of Medicine· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Bayer· Source

• Completed

  Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

  NCT04693715· Phase 2· Revalesio Corporation· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Phase 2· Gossamer Bio USA, Inc.· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

  NCT04266197· Phase 2· Respira Therapeutics, Inc.· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Laekna Limited· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial

  NCT04069312· Phase 3· Johns Hopkins University· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Washington University School of Medicine· Source

• Completed

  Optimize PRO Study

  NCT04091048· Medtronic Cardiovascular· Source

• Completed

  SVC Occlusion in Subjects With Acute Decompensated Heart Failure

  NCT03836079· Abiomed Inc.· Source

• Completed

  Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

  NCT03837327· Venn Biosciences Corporation· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

  NCT03656926· Phase 3· Zambon SpA· Source

• Completed

  Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

  NCT03657342· Phase 3· Zambon SpA· Source

• Completed

  DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation

  NCT03643224· Medtronic Cardiac Ablation Solutions· Source

• Completed

  TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

  NCT03192462· Phase 1/2· Baylor College of Medicine· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· SWOG Cancer Research Network· Source

Showing 50 of 73.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke166 works · 18 trials
• Heart failure157 works · 16 trials
• Liver and biliary tract cancer78 works · 5 trials
• Coronary artery disease62 works · 12 trials
• Atrial fibrillation50 works · 7 trials
• Pulmonary arterial hypertension33 works · 12 trials
• Fatty liver disease (MASLD/MASH)27 works · 6 trials
• Triple-negative breast cancer26 works · 5 trials
• Cervical cancer22 works · 7 trials
• Spinal cord injury18 works · 4 trials
• Peripheral artery disease18 works · 4 trials
• Endometrial cancer18 works · 11 trials
• Aortic stenosis13 works · 12 trials
• Amyloidosis12 works · 6 trials
• Ventricular tachycardia9 works · 3 trials
• Hydrocephalus9 works · 0 trials
• Essential tremor8 works · 1 trial
• Sarcoidosis8 works · 0 trials
• Brain aneurysm7 works · 1 trial
• Myasthenia gravis6 works · 6 trials
• Coeliac disease5 works · 0 trials
• Gastroparesis5 works · 0 trials
• Graves' disease and hyperthyroidism4 works · 0 trials
• Sjögren's disease3 works · 0 trials